4//SEC Filing
DILLY STEPHEN GEORGE 4
Accession 0001209191-22-040252
CIK 0001290149other
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 4:35 PM ET
Size
15.2 KB
Accession
0001209191-22-040252
Insider Transaction Report
Form 4
DILLY STEPHEN GEORGE
DirectorCEO and President
Transactions
- Disposition to Issuer
Common Stock
2022-07-01$55.00/sh−5,000$275,000→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−520,000→ 0 totalExercise: $14.03Exp: 2030-06-01→ Common Stock (520,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−260,000→ 0 totalExercise: $12.15Exp: 2030-08-12→ Common Stock (260,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−92,000→ 0 totalExercise: $16.73Exp: 2031-03-15→ Common Stock (92,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−165,000→ 0 totalExercise: $31.54Exp: 2032-03-14→ Common Stock (165,000 underlying)
Footnotes (5)
- [F1]The option vested as to 25% of the total shares on June 1, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on June 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
- [F3]On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
- [F4]The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
- [F5]The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.
Documents
Issuer
Sierra Oncology, Inc.
CIK 0001290149
Entity typeother
Related Parties
1- filerCIK 0001389147
Filing Metadata
- Form type
- 4
- Filed
- Jun 30, 8:00 PM ET
- Accepted
- Jul 1, 4:35 PM ET
- Size
- 15.2 KB